Sign in

Private company

BioPlus Acquisition Corp.

Electromedical and electrotherapeutic apparatus company in the Cayman Islands1

In its 2023 annual report the company says: “We are an early stage blank check company formed as a Cayman Islands exempted company incorporated for the purpose of effecting an initial business combination.”31 It is headquartered in New York, New York.1

Last updated Oct 21, 2026.

Overview

$2.0MNet income, fiscal 20222
  • IndustryElectromedical & Electrotherapeutic Apparatus1
  • HeadquartersNew York, New York1
  • Incorporated inCayman Islands3
  • Business address260 Madison Avenue, Suite 800, New York, Ny 100163
  • Filer category, Emerging growth company3

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Fiscal year20212022
Operating income-$1.2M2
Net income$2.0M2

Compare BioPlus Acquisition Corp. with another company

Corporate structure

BioPlus Acquisition Corp. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of BioPlus Acquisition Corp.

  • BioPlus Acquisition Corp. New York, New York

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What BioPlus Acquisition Corp. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$635.5K7 Dec 31, 2021$07 Feb 10, 2021

Leadership

Who has led BioPlus Acquisition Corp., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ross Haghighat2021

Chief financial officer

  1. Ross Haghighat2021
2025
Board members and other officers (9)

Timeline

  1. Oct 4, 20238-K Entered a material agreement; Ended a material agreement; Other events17
  2. Jun 14, 20238-K Regulation FD disclosure18
  3. Jun 8, 20238-K Entered a material agreement; New debt or obligation; Unregistered sale of shares19
  4. May 30, 20238-K Regulation FD disclosure20
  5. May 3, 20238-K Entered a material agreement; Regulation FD disclosure21
  6. Oct 11, 20228-K Other events22
  7. Dec 13, 20218-K Other events23
  8. Dec 8, 20218-K Entered a material agreement; Unregistered sale of shares; Bylaws or fiscal year changed24
  9. Dec 2, 2021New chief executive Ross Haghighat becomes CEO9

Filings

69 filings to the SEC since October 2021: 2 annual reports, 5 quarterly reports, 8 major events, 10 insider forms, 16 large holders, 28 other. The latest 20:

  1. Feb 12, 2024SC 13G/A AMENDMENT NO. 2 TO SCHEDULE 13G EDGAR
  2. Feb 9, 2024SC 13G/A BIOPLUS ACQUISITION CORP 13GA EDGAR
  3. Feb 7, 2024SC 13G/A EDGAR
  4. Jan 19, 2024SC 13G/A BIOPLUS ACQUISITION CORP. EDGAR
  5. Oct 16, 202315-12G EDGAR
  6. Oct 4, 2023RW EDGAR
  7. Oct 4, 20238-K CURRENT REPORT EDGAR
  8. Sep 15, 2023425 EDGAR
  9. Aug 16, 2023425 EDGAR
  10. Aug 14, 202310-Q EDGAR
  11. Aug 1, 2023S-4/A EDGAR
  12. Jul 17, 2023425 EDGAR
  13. Jun 30, 2023S-4/A EDGAR
  14. Jun 14, 2023425 EDGAR
  15. Jun 14, 20238-K EDGAR
  16. Jun 13, 2023SC 13D/A EDGAR
  17. Jun 12, 20234 FORM 4 SUBMISSION EDGAR
  18. Jun 8, 20238-K EDGAR
  19. May 30, 2023425 EDGAR
  20. May 30, 20238-K EDGAR

The 69 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How BioPlus Acquisition Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARBioPlus Acquisition Corp.1
  • CIK0001856653
  • Employer ID (EIN)98-15832721
  • Filer status<br>emerging growth company1
  • Incorporated inCayman Islands1
  • Fiscal year endsDecember 311
  • Industry code (SIC)3845 Electromedical & Electrotherapeutic Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address260 Madison Avenue, Suite 800, New York, NY 100161
  • Phone21228740921
  • Public float$230.4M as of Jun 30, 20222
  • On EDGAR sinceJun 22, 20211
  • Filings73 in all: 425 (9), 3 (8), 8-K (8), SC 13G/A (8), SC 13G (6), 10-Q (5), CORRESP (3), UPLOAD (3)1
    All 27 form types

    10-K (2), 4 (2), S-1/A (2), S-4/A (2), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERT (1), DEF 14A (1), DRS (1), EFFECT (1), PRE 14A (1), RW (1), S-1 (1), S-1MEF (1), S-4 (1), SC 13D (1), SC 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2023
    Quarterly report (10-Q) Aug 14, 2023
    Proxy statement (DEF 14A) May 12, 2023
    Latest 8-K (8-K) Oct 4, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
    SEC EDGAROther events
  23. 23
    SEC EDGAROther events
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31